There are 2185 resources available
612O - Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
Presenter: Maria Vieito
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
1926MO - Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada
Presenter: Laura Locati
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
LBA39 - Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
Presenter: Adam Yopp
Session: Proffered paper session 1: GI tumours, upper digestive
Resources:
Abstract
989O - Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial
Presenter: Angelica Loskog
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
1720MO - A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
Presenter: Evan Rosenbaum
Session: Mini oral session: Sarcoma
Resources:
Abstract
1721MO - Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma
Presenter: Florence Duffaud
Session: Mini oral session: Sarcoma
Resources:
Abstract
1145MO - CVM-005: Phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in advanced neuroendocrine tumors (NET) after progression on prior therapy
Presenter: Chia Jui Yen
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
LBA19 - Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
Presenter: Heather McArthur
Session: Proffered paper session: Breast cancer, metastatic
Resources:
Abstract
605O - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Presenter: Hongyun Zhao
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
Presenter: Haibo Qiu
Session: Mini oral session: Sarcoma
Resources:
Abstract